Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF<sup>V600E</sup>.

Oncotarget · 2017 · PMC5689570 · PMID 29156680

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

We analyzed the PTC TCGA data set [ 1 ]; 5p showed a trend in increase of copy-number (0.2 cutoff) from stage I (0%) to stage III (3.5%) in BRAF V600E -PTC, and from 1.03% in stage I to 13.04% in stage III in BRAF WT -PTC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.